Sanna M Goyert

US Patent:

58041893, Sep 8, 1998

Filed:

Jun 6, 1994

Appl. No.:

8/254095

Inventors:

Sanna M. Goyert - New York NY

International Classification:

A61K 3817

US Classification:

4241851

Abstract:

Methods are provided for the treatment of symptoms of sepsis and other conditions that are mediated by the action of CD14 myelomonocytic antigen ("CD14"). The embodiments herein include treatments for symptoms of sepsis that are triggered by lipopolysaccharide ("LPS"). A genetically engineered recombinant soluble CD14 ("rsCD14") and fragments thereof are also provided. Both rsCD14 and a fragment thereof have been isolated and purified. The rsCD14 or fragments thereof can be administered to mammals to prevent or treat symptoms that are associated with sepsis.

US Patent:

55433030, Aug 6, 1996

Filed:

Dec 13, 1993

Appl. No.:

8/165583

Inventors:

Sanna M. Goyert - New York NY

International Classification:

C12N 1512
C12N 1585
C12N 1574
C12N 506

US Classification:

435 691

Abstract:

A recombinant myelomonocytic differentiation antigen CD14 has a primary amino acid sequence substantially equivalent to that of native human CD14. A process for isolating a DNA clone pCD-CD14 encoding CD14 comprises cell surface screening of COS 7 cells transfected with expressible DNA clones by monoclonal antibodies to CD14.